Challenging Clinical Issues on the Interaction Between Addiction and Hyperalgesia

Opioid-Induced Hyperalgesia

Volumn , Issue , 2016, Pages 74-94

  Ling, Walter ^a   Compton, Peggy ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882653968     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420089004-9     Document Type: Chapter

References (151)

1. Mitchell SW. Characteristics. New York: The Century Company, 1905: 21.
2. Albutt C. On the abuse of hypodermic injections of morphia. Practitioner 1870; 3: 327-330.
3. Angst MJ, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006; 104: 6570-687.
4. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am 2007; 91: 199-211.
5. Chu LF, Angst MS, Clark JD. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24: 479-496.
6. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for post-operative pain. Best Pract Res Clin Anesthesiol 2007; 21: 65-83.
7. Martin J, Inglis J. Pain tolerance and narcotic addiction. Br J Sociol Clin Psychol 1965; 4: 224-229.
8. Ho A, Dole V. Pain perception in drug-free and in methadone-maintained human ex-addicts. Proc Soc Exp Biol Med 1979; 162: 392-395.
9. Compton MA. Cold pressor pain tolerance in opiate and cocaine abusers: Correlates of drug type and use status. J Pain Symptom Manage 1994; 9: 462-473.
10. Compton P, Charuvastra C, Kintaudi K, et al. Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manag 2000; 20: 237-245.
11. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63: 139-146.
12. Doverty M, White JM, Somogyi AA, et al. Hyperalgesic responses in methadone maintenance patients. Pain 2001; 90: 91-96.
13. Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001; 93: 155-163.
14. Schall U, Katta T, Pries E, et al. Pain perception of intravenous heroin users on maintenance therapy with levomethadone. Pharmacopsychiatry 1996; 29: 176-179.
15. Compton PA, Ling W, Torrington MA. Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients. Addict Biol 2008; 13: 393-402.
16. Athanasos P, Smith CS, White JM, et al. Methadone maintenance patients are cross tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain 2006; 120: 267-275.
17. Pud D, Cohen D, Lawental E, et al. Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend 2006; 82: 218-223.
18. Mogil JS, Kest B, Sadowski B, et al. Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther 1996; 276: 532-544.
19. Mogil JS, Wilson SG, Bon K, et al. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 1999; 80: 67-82.
20. Elmer GI. Differences in morphine reinforcement property in two inbred rat strains: associations with cortical receptors, behavioral activity, analgesia and the cataleptic effects of morphine. Psychopharmacology (Berlin) 1993; 112: 183-188.
21. Elmer GI, Pieper JO, Goldberg SR, et al. Opioid operant self-administration, analgesia, stimulation and respiratory depression in mu-deficient mice. Psychopharmacology (Berlin) 1995; 117: 23-31.
22. Elmer GI, Pieper JO, Negus SS, et al. Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests. Pain 1998; 75: 129-240.
23. Oliverio A, Castellano C, Eleftheriou BE. Morphine sensitivity and tolerance: a genetic investigation in the mouse. Psychopharmacologia 1975; 42: 219-224.
24. Semenova S, Kuzmin A, Zvartau E. Strain differences in the analgesic and reinforcing action of morphine in mice. Pharmacol Biochem Behav 1995; 50: 17-21.
25. Oliverio A, Castellano C. Genotype-dependent sensitivity and tolerance to morphine and heroin: dissociation between opiate-induced running and analgesia in the mouse. Psychopharmacologia 1974; 39: 13-22.
26. Wilson SG, Smith SB, Chesler EJ, et al. The heritability of antinociception: common pharmacogenetic mediation of five neurochemically distinct analgesics. J Pharmacol Exp Ther 2003; 304: 547-559.
27. Lariviere WR, Wilson SG, Laughlin TM, et al. Heritability of nociception. III. Genetic relationships among commonly used assays of nociception and hypersensitivity. Pain 2002; 97: 75-86.
28. Liang DY, Guo T, Liao G, et al. Chronic pain and genetic background interact and influence opioid analgesia, tolerance, and physical dependence. Pain 2006; 121: 232-240.
29. Brase DA, Loh HH, Way EL. Comparison of the effects of morphine on locomotor activity, analgesia and primary and protracted physical dependence in six mouse strains. J Pharmacol Exp Ther 1977; 201: 368-374.
30. Racagni G, Bruno F, Iuliano E, et al. Differential sensitivity to morphine-induced analgesia and motor activity in two inbred strains of mice: behavioral and biochemical correlations. J Pharmacol Exp Ther 1979; 209: 111-116.
31. Gwynn GJ, Domino EF. Genotype-dependent behavioral sensitivity to mu vs. kappa opiate agonists. II. Antinociceptive tolerance and physical dependence. J Pharmacol Exp Ther 1984; 231: 312-316.
32. Moskowitz AS, Terman GW, Carter KR, et al. Analgesic, locomotor and lethal effects of morphine in the mouse: strain comparisons. Brain Res 1985; 361: 46-51.
33. Belknap JK, Mogil JS, Helms ML, et al. Localization to chromosome 10 of a locus influencing morphine analgesia in crosses derived from C57BL/6 and DBA/2 strains. Life Sci 1995; 57: PL117-PL124.
34. Berrettini WH, Ferraro TN, Alexander RC, et al. Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 1994; 7: 54-58.
35. Liang DY, Liao G, Lighthall GK, et al. Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogenet Genomics 2006; 16: 825-835.
36. Petruzzi R, Ferraro TN, Kürschner VC, et al. The effects of repeated morphine exposure on mu opioid receptor number and affinity in C57BL/6J and DBA/2J mice. Life Sci 1997; 61: 2057-2064.
37. Mogil JS, Przemyslaw M, Flodman P, et al. One or two genetic loci mediate high opiate analgesia in selectively bred mice. Pain 1995; 60: 125-135.
38. Moskowitz AS, Goodman RR. Autoradiographic analysis of mu1, mu2, and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid receptor-deficient) mice. Brain Res 1985; 360: 108-116.
39. Compton P, Alarcon M, Geschwin D. Role of the m-opioid receptor gene in human pain tolerance and opioid addiction. Drug Alcohol Depend 2001; 63: S30-S31.
40. Edwards RR. Genetic predictors of acute and chronic pain. Curr Rheumatol Rep 2006; 8: 411-417.
41. Mogil JS, Yu L, Basbaum AI. Pain genes? Natural variation and transgenic mutants. Annu Rev Neurosci 2000; 23: 777-811.
42. Oertel B, Lötsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 2008; 9: 179-194.
43. Stamer UM, Stüber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 2007; 20: 478-484.
44. Flores CM, Mogil JS. The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics 2001; 2: 177-194.
45. Lötsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004; 43: 983-1013.
46. Stamer UM, Stüber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007; 8: 2235-2245.
47. Mayer P, Höllt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006; 16: 1-7.
48. Ikeda K, Ide S, Han W, et al. How individual sensitivity to opiates can be predicted by genetic analyses. Trends Pharmacol Sci 2005; 26: 311-317.
49. Kest B, Hopkins E, Palmese CA, et al. Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. Pharmacol Biochem Behav 2002; 73: 821-828.
50. Kest B, Palmese CA, Hopkins E, et al. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 2002; 115: 463-469.
51. Kest B, Palmese CA, Juni A, et al. Mapping of a quantitative trait locus for morphine withdrawal severity. Mamm Genome 2004; 15: 610-617.
52. Lötsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J 2006; 6: 200-210.
53. Kim H, Neubert JK, Miguel AS, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004; 109: 488-496.
54. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 14: 306-313.
55. McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002; 7: 52-58.
56. Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005; 42: 583-587.
57. Li X, Angst MS, Clark D. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res 2001; 86: 56-62.
58. Liebmann P, Lehofer M, Schonauer-Cejpek M, et al. Pain sensitivity in former opioid addicts. Lancet 1994; 344: 1031-1032.
59. Liebmann P, Lehofer M, Moser M, et al. Persistent analgesia in former opiate addicts is resistant to blockade of endogenous opioids. Biol Psychiatry 1997; 42: 962-964.
60. Liebmann P, Lehofer M, Moser M, et al. Nervousness and pain sensitivity. II. Changed relation in ex-addicts as a predictor for early relapse. Psychiatry Res 1998; 79: 55-58.
61. Prosser JM, Steinfeld M, Cohen LJ, et al. Abnormal heat and pain perception in remitted heroin dependence months after detoxification from methadone-maintenance. Drug Alcohol Depend 2008; 95: 237-244.
62. Devillers JP, Boisserie F, Laulin JP, et al. Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Brain Res 1995; 700: 173-181.
63. Dunbar SA, Pulai IJ. Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat. J Pharmacol Exp Ther 1998; 284: 678-686.
64. Ekblom M, Hammerlund-Udenaes M, Paalzow L. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. J Pharmacol Exp Ther 1993; 266: 244-252.
65. Grilly DM, Gowans GC. Acute morphine dependence: effects observed in shock and light discrimination tasks. Psychopharmacology (Berlin) 1986; 88: 500-504.
66. Johnson SM, Duggan AW. Tolerance and dependence of dorsal horn neurons of the cat: the role of the opiate receptors of the substantia gelatinosa. Neuropharmacology 1981; 20: 1033-1038.
67. Laulin JP, Larcher A, Celerier E, et al. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci 1998; 10: 782-785.
68. Donnerer J. Primary sensory neurons and naloxone-precipitated morphine withdrawal. Br J Pharmacol 1989; 86: 767-772.
69. Kaplan H, Fields HL. Hyperalgesia during acute opioid abstinence: evidence for a nociceptive facilitating function of the rostral ventromedial medulla. J Neurosci 1991; 11: 1433-1439.
70. Martin WR, Eades CG. A comparison between acute and chronic physical dependence in the chronic spinal dog. J Pharmacol Exp Ther 1964; 146: 385-394.
71. Martin WR, Gilbert PE, Jasinski PE, et al. An analysis of naltrexone precipitated abstinence in morphine-dependent chronic spinal dogs. J Pharmacol Exp Ther 1987; 240: 565-570.
72. Tilson HA, Rech RH, Stolman S. Hyperalgesia during withdrawal as a means of measuring the degree of dependence in morphine dependent rats. Psychopharmacologia 1973; 28: 287-300.
73. Yaksh TL, Harty GJ, Onofrio BM. High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 1986; 64: 590-597.
74. Bederson JB, Fields HL, Barbaro NM. Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosens Mot Res 1990; 7: 185-203.
75. Goldfarb J, Kaplan EI, Jenkins HR. Interaction of morphine and naloxone in acute spinal cats. Neuropharmacology 1978; 17: 569-575.
76. Kim DH, Barbaro NM, Fields HL. Dose response relationship for hyperalgesia following naloxone precipitated withdrawal from morphine. Soc Neurosci Abstr 1988; 14: 174.
77. Kim DH, Fields HL, Barbaro NM. Morphine analgesia and acute physical dependence: rapid onset of two opposing, dose-related processes. Brain Res 1990; 516: 37-40.
78. Ibuki T, Dunbar SA, Yaksh TL. Effect of transient naloxone antagonism in tolerance development in rats receiving continuous spinal morphine infusion. Pain 1997; 70: 125-132.
79. Li X, Angst MS, Clark D. Opioid-induced hyperalgesia incisional pain. Anaesth Analg 2001; 93: 204-209.
80. Celerier E, Laulin JP, Larcher A, et al. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res 1999; 847: 18-25.
81. Celerier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventative effect of ketamine. Anesthesiology 2000; 92: 465-472.
82. Dunbar S, Yaksh TL. Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Anesthesiology 1996; 84: 1177-1188.
83. Larcher A, Laulin JP, Celerier E, et al. Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspertate-dependent pain facilitatory systems. Neuroscience 1998; 84: 583-589.
84. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995; 1: 353-364.
85. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259-274.
86. Mayer DJ, Mao J, Holt J, et al. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 1999; 96: 7731-7736.
87. Chu L, Angst M, Clark, D. Opioids in non-cancer pain: measurement of opioidinduced tolerance and hyperalgesia in pain patients on chronic opioid therapy. J Pain 2004; 5: S73.
88. Holtman JR, Wala EP. Characterization of morphine-induced hyperalgesia in male and female rats. Pain 2005; 114: 62-70.
89. Ossipov MH, Lai J, King T, et al. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Pept Sci 2005; 80: 319-324.
90. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 4th ed., Text Revision. Arlington, VA: American Psychiatric Association, 2000.
91. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003; 106: 49-57.
92. Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 2003; 97: 810-815.
93. Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain 2003; 4: 511-519.
94. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002; 100: 213-217.
95. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7: 43-48.
96. Koppert W, Angst M, Alsheimer M, et al. Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain 2003; 106: 91-99.
97. Simonnet G. Opioids: from analgesia to anti-hyperalgesia? Pain 2005; 118: 8-9.
98. Vanderah TW, Ossipov MH, Lai J, et al. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 2001; 92: 5-9.
99. Mercadante S, Ferrera P, Villari P, et al. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003; 26: 769-775.
100. Wilder-Smith OH, Arendt-Nielsen L. Postoperative hyperalgesia: its clinical importance and relevance. Anesthesiology 2006; 104: 601-607.
101. Van Elstraete AC, Sitbon P, Trabold F, et al. A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: The protective effect of prior administration of ketamine. Anesth analg 2005; 101: 1750-1756.
102. Gardell LR, King T, Ossipov MH, et al. Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett 2006; 396: 4449.
103. Richebe P, Rivat C, Creton C, et al. Nitrous oxide revisited. Anesthesiology 2005; 105: 845-854.
104. Colpaert FC. System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol Rev 1996; 48: 355-402.
105. Laulin JP, Celerier E, Larcher A, et al. Opiate tolerance to daily heroin administration: An apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 1999; 89: 631-636.
106. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 2006; 10: 67-70.
107. Colpaert FC. Mechanisms of opioid-induced pain and antinociceptive tolerance: signal transduction. Pain 2002; 95: 287-288.
108. Celerier E, Laulin JP, Corcuff JB, et al. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 2001; 21: 4074-4080.
109. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.
110. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med 2003; 348: 1279-1281.
111. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acids receptors and protein kinase C. J Neurosci 1994; 14: 2301-2312.
112. Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22: 6747-6755.
113. Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074-7079.
114. King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioidinduced hyperalgesia. Pain 2005; 116: 276-288.
115. King T, Ossipov MH, Vanderah TW, et al. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005; 14: 194-205.
116. Ossipov MH, Lai J, King T, et al. Antinociceptive and nociceptive actions of opioids. J Neurobiol 2004; 61: 146-148.
117. Xie JY, Herman DS, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci 2005; 25: 409-416.
118. Vanderah T, Suenaga N, Ossipov M, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001; 21: 279-286.
119. De Leo JA, Tanga FY, Tawfik VL. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 2004; 10: 40-52.
120. Watkins LR, Maier SF. The pain of being sick: Implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000; 51: 29-57.
121. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001; 39: 281-286.
122. Johnston IN, Westbrook RF. Inhibition of morphine analgesia by LPS: role of opioid and NMDA receptors and spinal glia. Behav Brain Res 2005; 156: 75-83.
123. Johnston IN, Milligan ED, Wieseler-Frank J. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004; 24: 7353-7365.
124. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002; 22: 9980-9989.
125. Tai YH, Wang YH, Wang JJ, et al. Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats. Pain 2006; 124: 77-86.
126. Cohen SP, Christo PJ, Wang S, et al. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med 2008; 33: 199-206.
127. Sweitzer SR, Allen CP, Zissen MH, et al. Mechanical allodynia and thermal hyperalgesia upon acute opioid withdrawal in the neonatal rat. Pain 2004; 110: 269-280.
128. Helmy SA, Bali A. The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements. Anesth Analg 2001; 92: 739-744.
129. Weinbroum A, Rudick V, Paret G, et al. The role of dextromethorphan in pain control. Can J Anaesthia 2000; 47: 585-596.
130. Dudgeon DJ, Bruera E, Gagnon B, et al. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage 2007; 33: 365-371.
131. Galer BS, Lee D, Ma T, et al. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 2005; 115: 284-295.
132. Haugan F, Rygh LJ, Tjølsen A. Ketamine blocks enhancement of spinal long-term potentiation in chronic opioid treated rats. Acta Anaesthesiol Scand 2008; 52: 681-687.
133. Heiskanen T, Härtel B, Dahl ML, et al. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 2002; 96: 261-267.
134. Chaplan SR, Malmberg AB, Yaksh TL. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 1997; 280: 829-838.
135. Singler B, Tröster A, Manering N, et al. Modulation of remifentanil-induced postinfusion hyperalgesia by propofol. Anesth Analg 2007; 104: 1397-1403.
136. Joshi W, Connelly NR, Reuben SS, et al. An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg 2003; 97: 35-38.
137. Tröster A, Sittl R, Singler B, et al. Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans. Anesthesiology 2006; 105: 1016-1023.
138. Bernstein ZP, Yucht S, Battista E, et al. Proglumide as a morphine adjunct in cancer pain management. J Pain Symptom Manage 1998; 15: 314-320.
139. McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine. Clin J Pain 2003; 19: 200-201.
140. McCleane GJ. Cholecystokinin antagonists a new way to improve the analgesia from old analgesics? Curr Pharm Des 2004; 10: 303-314.
141. Carroll IR, Angst MS, Clark JD. Management of perioperative pain in patients chronically consuming opioids. Reg Anesth Pain Med 2004; 29: 576-591.
142. Cepeda MS, Alvarez H, Morales O, et al. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004; 107: 41-46.
143. Terner JM, Barrett AC, Lomas LM, et al. Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain 2006; 122: 90-101.
144. Wang HY, Friedman E, Olmstead MC, et al. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005; 135: 247-261.
145. Webster LR. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 2007; 16: 1277-1283.
146. Chindalore VL, Craven RA, Yu KP, et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005; 6: 392-399.
147. Webster LR, Butera PG, Moran LV, et al. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006; 7: 937-946.
148. Sloan P, Harmann S. Ultra-low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manage 2006; 2: 295-304.
149. Chia YY, Liu K, Wang JJ, et al. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth 1999; 46: 872-827.
150. Cooper DW, Lindsay SL, Ryall DM, et al. Does intrathecal fentanyl produce acute cross-tolerance to IV morphine? Br J Anaesth 1997; 78: 311-313.
151. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93: 409-417.